Purdue’s confirmed Plan of Reorganization (“Plan”) was vacated on appeal by the United States District Court for the Southern District of New York. Purdue is appealing the ruling while simultaneously continuing its efforts to forge yet further consensus around a Plan that will deliver billions of dollars to the American people for opioid abatement. The District Court decision does not affect Purdue’s operational stability or its ability to produce its many medications safely and effectively. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners, customers, and consumers. The company continues serving patients and consumers who rely on its medicines and products, pursuing its pipeline, and introducing medicines that will help save and improve lives.
Rhodes Pharmaceuticals L.P. has developed and distributed quality pharmaceutical products nationwide since 2008. With our R&D capabilities, industry partnerships, broad customer base, and strong relationships with suppliers, we offer reliable supply of high-quality products at competitive prices. Rhodes is a wholly-owned subsidiary of Purdue Pharma L.P.
Our management team has extensive experience in the pharmaceutical industry.
Strong focus on product development of quality products highlighted by exceptional manufacturing and distribution strategies.
Our goal is to provide unparalleled delivery of quality pharmaceutical products while continuing to build lasting relationships within the pharmaceutical community.
We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.